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provide a rare opportunity to ascertain its role in man.  Meth-
ods: Retrospective review of patients with INSR mutations. 
Data for BP, renal imaging, plasma creatinine and electrolyte 
levels, as well as urine protein, albumin and calcium excre-
tion were sought from the treating clinicians.  Results: From 
33 patients with INSR mutations, data were available for 17 
patients. Plasma creatinine was low (mean ± SD: 25 ± 9 
μmol/l) and mean plasma electrolyte concentrations were 
within the normal range (n = 13). Systolic BP ranged between 
the 18th and 91st percentile for age, sex, height and weight 
(n = 9; mean ± SD: 49 ± 24). Twenty-four-hour urinary calci-
um data were available from 10 patients and revealed hyper-
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 Abstract 
 Background/Aims: Donohue and Rabson-Mendenhall syn-
drome are rare autosomal recessive disorders caused by mu-
tations in the insulin receptor gene,  INSR . Phenotypic fea-
tures include extreme insulin resistance, linear growth retar-
dation, paucity of fat and muscle, and soft tissue overgrowth. 
The insulin receptor is also expressed in the kidney, where 
animal data suggest it plays a role in glomerular function and 
blood pressure (BP) regulation, yet such a role in the human 
kidney is untested. Patients with biallelic INSR mutations 
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calciuria in all (mean ± SD: 0.32 ± 0.17 mmol/kg/day; normal 
<0.1). Nephrocalcinosis was present in all patients (n = 17). 
Urinary albumin excretion (n = 7) ranged from 4.3–122.5 μg/
min (mean ± SD: 32.4 ± 41.0 μg/min; normal <20).  Conclu-
sions: INSR dysfunction is associated with hypercalciuria and 
nephrocalcinosis. No other consistent abnormality of renal 
function was noted. Normotension and stable glomerular 
function with only moderate proteinuria is in contrast to ge-
netically modified mice who have elevated BP and progres-
sive diabetic nephropathy.  © 2014 S. Karger AG, Basel 
 Introduction 
 Donohue syndrome (DS) and Rabson-Mendenhall 
syndrome (RMS) are rare autosomal recessive disorders. 
Initially described as distinct entities, they have subse-
quently been found to be caused by mutations in the in-
sulin receptor gene (INSR). They are characterized by in-
trauterine and postnatal growth restriction, paucity of 
adipose tissue, overgrowth of many soft tissues including 
skin, hair and teeth, and characteristically coarse facial 
features, as well as severely abnormal glucose homeosta-
sis and extreme insulin resistance. DS denotes the more 
severe end of the symptom spectrum and is often associ-
ated with death in the first year of life. It was first de-
scribed by Donohue in 1948  [1] , and termed ‘lepre-
chaunism’ in 1954  [2] . RMS, originally described in 1956 
 [3] , generally is taken to encompass slightly less severely 
affected patients, although the distinction between DS 
and RMS is not strictly defined. RMS also features linear 
growth impairment, soft tissue overgrowth, and coarse 
features. The severe insulin resistance leads to hyperinsu-
linism with pancreatic β-cell decompensation, diabetes, 
hyperglycemia and ultimately ketoacidosis, usually to-
wards the end of the first or in the second decade, as well 
as hyperandrogenism. Early mortality due to advanced 
complications of diabetes is common  [4] . A more com-
mon but less severe phenotype, often called type A insulin 
resistance, features insulin-resistant diabetes and hyper-
androgenism that usually is identified peri- or postpuber-
tally. In most causes this is accounted for by dominant 
negative heterozygous mutations in the tyrosine kinase 
domain of the receptor, however a minority of cases are 
caused by biallelic, presumably less deleterious, α-subunit 
mutations  [4] . 
 The INSR is expressed throughout the nephron  [5, 6] , 
but little is known about its precise role. In vivo perfusion 
experiments in rabbits showed a positive effect of insulin 
on proximal tubular sodium reabsorption  [7] , yet the ab-
sence of insulin signaling in mice with kidney-specific de-
letion of INSR is also associated with enhanced sodium 
reabsorption and consequent elevated blood pressure 
(BP)  [8] . Podocyte-specific deletion of the receptor in 
mice has been reported to lead to direct remodeling of the 
actin cytoskeleton with consequent proteinuria and fea-
tures of diabetic nephropathy  [9] . Recently, INSR has also 
been implicated in magnesium homoeostasis  [10, 11] . Pa-
tients with impaired INSR function provide a unique op-
portunity to study the role of this receptor in human kid-
ney. So far, only case reports and small case series exist in 
the literature, reporting an association with medullary 
sponge kidney  [12, 13] , and a Bartter-like phenotype  [14] . 
In order to get a better understanding, we performed a 
medical note review of the renal features of INSR dys-
function in the largest series of patients reported so far.
 Materials and Methods 
 Subjects with severe insulin resistance and a clinical diagnosis 
of DS or RMS were recruited for research studies with informed 
consent in line with procedures approved by either the local re-
search ethics committee in Cambridge, UK, or the institutional 
review board of the National Institute of Diabetes and Digestive 
and Kidney Diseases, USA.
 Information on BP, renal ultrasound, urine output, plasma cre-
atinine and electrolytes, as well as urine protein, albumin and cal-
cium excretion were sought for those patients with confirmed 
 INSR mutations. If multiple datasets were available from the same 
patient, the most recent and most complete dataset was used.
 Results 
 From a research database of 33 patients with  INSR mu-
tations, data on renal features were available for 17 pa-
tients from the clinicians contacted, although the com-
plete dataset was only available for 8 cases ( table 1 ).
 General Characteristics and INSR Mutations 
 Age at last follow-up varied between 4 months and 24 
years. Seven patients had a clinical diagnosis of DS and 10 
of RMS. Mutations and/or clinical data not pertaining to 
kidney function have been previously reported for 9 of 
the patients  [4, 15–19] . Previously unreported mutations 
include four altering conserved residues in the L1 domain 
of the α-subunit (p.L109R, p.R114W, p.G84Q, p.V66A), 
and one affecting a conserved residue in the extracellular 
β-subunit (p.R899Q).
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 Blood Pressure 
 Due to the discordant animal model results with re-
spect to insulin signaling and BP  [7, 8] , we first reviewed 
BPs of the patients. As systolic BP is more reliably mea-
sured, especially in small children, we concentrated on 
these and translated them into centile values, based on 
age, sex, height and weight. BP data were available from 
9 children and the mean centile was the 49th, albeit with 
a wide range (18th–91st).
 Glomerular Function 
 Data from genetically modified mice suggested a crit-
ical role for Insr in podocyte function  [9] and we there-
fore assessed glomerular filtration rate, protein and al-
buminuria. Formal GFR measurements were not avail-
able, but plasma creatinine values were in the low-normal 
range for age in the 13 patients with available data. Six 
patients had proteinuria quantified via a 24-hour urine 
collection with mean proteinuria being 10.1 mg/m 2 /h 
(range 0.48–27.16) and thus just above the upper limit 
of normal (<4 mg/m 2 /h). Similarly, 24-hour data on al-
buminuria were available from 7 patients with mean al-
bumin excretion being 32.4 μg/min (range 4.3–122.5), 
thus again just above the upper limit of normal (<20 μg/
min).
a b c
d e f
g h i
j k l
a b
 Fig. 1. Representative ultrasound images 
detailing nephrocalcinosis. Shown are ul-
trasound images of kidneys from patient 1, 
right kidney, age 10 years ( a ), patient 3, age 
16 years ( b ), patient 4, left kidney, age 24 
years ( c ), patient 8, left kidney, age 12 years 
( d ), patient 5, age 9 months ( e ), patient 9, 
left kidney, age 14 years ( f ), patient 10, right 
kidney, age 17 years ( g ), patient 12, left kid-
ney, age 6 months ( h ), patient 13, right kid-
ney, age 8 years ( I ), patient 14, left kidney, 
age 13 years ( j ), patient 15, left kidney, age 
13 years ( k ), and patient 16, left kidney, age 
3 months ( l ). Note the varying pattern of 
nephrocalcinosis by ultrasound, ranging 
from isolated echodensities to a general-
ized punctuate pattern to medullary neph-
rocalcinosis.  
 Fig. 2. Representative CT images detailing 
nephrocalcinosis. Shown are abdominal 
CT images from patient 4, age 24 years ( a ) 
and patient 5, age 9 months ( b ). Note the 
calcium densities in the kidneys (arrows).  
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 Plasma Electrolytes, Renin and Aldosterone, 
Parathyroid Hormone and Vitamin D 
 Plasma electrolytes were generally in the normal range, 
although mean plasma potassium was in the low-normal 
range at 3.78 mmol/l, with 3 patients being hypokalemic 
(<3.5 mmol/l;  table 1 ). Similarly, mean plasma chloride 
level was in the low-normal range at 101 mmol/l, with 3 
patients having values below the norm. Mean plasma bi-
carbonate concentration was in the high normal range at 
26 mmol/l. Hypokalemic, hypochloremic alkalosis sug-
gests activation of the renin-aldosterone system. Unfor-
tunately, renin and aldosterone values were available in 
only 4 patients and showed slightly elevated renin activ-
ity [13 (patient 12), 37 (patient 13) and 8.7 (patient 14) 
pmol/ml/h and 162 mIU/l (patient 16; normal <40)], yet 
normal or even suppressed aldosterone values [400 (pa-
tient 12), <160 (patient 13), 170 (patient 14) and 320 (pa-
tient 16) pmol/l; normal <800]. Thus, the aldosterone/
renin ratio was low.
 Mean total plasma calcium level (n = 15) was normal 
at 2.28 mmol/l. Parathyroid hormone levels (n = 10) were 
in the low-normal range in all with a mean ± SD of 2.3 ± 
0.7 pmol/l (normal 0.3–5.9). 25-OH vitamin D levels were 
available in 9 patients and normal in all, ranging from 25 
to 128 nmol/l (mean ± SD: 73 ± 31; normal 25–200). Plas-
ma magnesium levels were in the low-normal range with 
a mean of 0.73 mmol/l (n = 13), with 5 patients being hy-
pomagnesemic ( table 1 ).
 Urine Volume  
 Data on 24-hour urine volume were available in 8 pa-
tients and urine output varied between 1.3 and 8.3 (mean 
± SD: 3.8 ± 1.8) ml/kg/h. 
 Urine Calcium Excretion 
 Twenty-four-hour urine calcium excretion was quan-
tified in 10 patients and ranged from 0.12 to 0.68 (mean 
± SD: 0.32 ± 0.17) mmol/kg/day, and was thus above the 
upper limit of normal (0.1 mmol/kg/day) in all.
 Nephrocalcinosis 
 Data relevant to nephrocalcinosis were available in all 
patients. All had renal ultrasound imaging reported as 
consistent with nephrocalcinosis. This was confirmed by 
CT in a further 2 patients ( fig. 1 ,  2 ). In 1 patient (patient 
12), nephrocalcinosis was even reported on an antenatal 
ultrasound.
 Discussion 
 We report the renal features in the largest series of pa-
tients with confirmed  INSR mutations to date in order to 
illuminate the role of the INSR in the kidney. Interest-
ingly, key features identified in this series are in contrast 
to some observations made in genetically modified ani-
mals, suggesting that there may be species-specific differ-
ences in INSR function in the kidney. Kidney-specific 
knockout of Insr in mice resulted in increased BP and 
impaired natriuresis suggesting that INSR is involved in 
BP regulation by enhancing sodium excretion  [8] . How-
ever, our data provide no evidence for enhanced sodium 
absorption in our patients as BPs were normal. Moreover, 
primary sodium retention would be expected to result in 
suppressed plasma renin activity yet this was actually 
slightly elevated in the 4 patients with these data available, 
albeit without concomitant hyperaldosteronism.
 Recently, the insulin receptor was reported to be criti-
cally important for glomerular function in mice: podo-
cyte-specific deletion of the  Insr gene is associated with 
albuminuria, glomerulosclerosis and chronic kidney dis-
ease  [9] . A biopsy in a patient with DS also showed fea-
tures of diabetic nephropathy  [20] . Moreover, in a long-
term follow-up (up to 30 years) report of 11 patients with 
INSR mutations (8 with type A insulin resistance and 3 
with RMS), nephropathy occurred in 5, including 1 of the 
RMS patients who had proteinuria of up to 600 mg/day 
 [4] . The low-grade proteinuria observed in our patients is 
in keeping with these findings, but there was no evidence 
of impaired kidney function at least as assessed by plasma 
creatinine. Whilst we recognize the imperfect nature of 
creatinine as a marker of glomerular filtration in these 
patients due to their low muscle mass, values remained 
very low up to 24 years of age. Kidney biopsies had not 
been performed in any of our patients, thus we are unable 
to comment on glomerulosclerosis, but it was not report-
ed in the autopsy findings of the original publications by 
Donohue  [1, 2] . This may reflect the age difference be-
tween the autopsy patients (infants) and the case report 
(10 years).
 Differences between mice and men have also been ob-
served for other important aspects of the phenotype of 
insulin receptor deficiency. Most strikingly,  Insr null 
mice die soon after birth of diabetic ketoacidosis  [21] , 
whereas humans with no functional insulin receptors 
seem protected from ketoacidosis at least in the early 
years of life  [22, 23] .
 The key renal features identified in our patients are 
hypercalciuria and nephrocalcinosis. This fits well with 
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original autopsy findings of intratubular calcium deposits 
reported by Donohue  [1, 2] . Interestingly, in 1 patient 
(patient 12) in whom antenatal ultrasound data were 
available, nephrocalcinosis was already reported before 
birth. Nephrocalcinosis has also been reported in other 
patients with DS  [14, 24] . The hypercalciuria in our pa-
tients was assessed by the gold standard of 24-hour urine 
collection, as the appropriateness of the calcium/creati-
nine ratio – commonly performed in children – is ques-
tionable in these patients: they are small for their age and 
have low apparent muscle mass, reflected in low plasma 
creatinine values with consequent lower than normal cre-
atinine excretion.
 The finding of hypercalciuria with INSR dysfunction 
fits well with the long-recognized hypercalciuria seen in 
patients with diabetes. The reversibility of this with insu-
lin treatment also supports a role for INSR in renal cal-
cium handling  [25] .
 Nevertheless, a key question arising from our observa-
tions is to what degree the renal manifestations result 
from a direct effect of the insulin receptor on renal func-
tion or merely reflect the altered metabolism and glucose 
handling in this condition or signaling through alterna-
tive pathways, such as the IGF receptor.
 Several lines of evidence support a primary role of the 
insulin receptor in renal calcium handling. We observed 
antenatal nephrocalcinosis in the 1 patient with available 
data, despite the ‘clamping’ of glucose levels in utero by 
the placenta. Although bone buffering of (keto)acidosis is 
thought to increase calcium release from bone with con-
sequent hypercalciuria  [26] , the patients described here 
were not acidotic at the time the calcium excretion was 
measured. In fact, the trend for increased plasma bicar-
bonate levels rather suggests metabolic alkalosis. Patients 
with the milder ‘type A’ form of INSR dysfunction who 
have hyperinsulinemic diabetes mellitus may develop 
features of diabetic nephropathy, yet have not been re-
ported to show nephrocalcinosis even when observed for 
many years  [4] .
 Obviously, the observational data provided here do 
not establish an underlying mechanism and the localiza-
tion of the tubular impairment in calcium reabsorption 
can only be speculated upon: the majority of filtered cal-
cium is reabsorbed passively in the proximal tubule 
 [27] , via a yet unidentified molecular pathway. There 
was no other evidence of proximal tubular dysfunction: 
low molecular weight protein excretion, the most sensi-
tive indicator of proximal tubular dysfunction  [28], was 
normal, as was renal phosphate and glucose handling 
(data not shown). This fits with animal data, as specific 
knockout of Insr in the proximal tubule also does not 
result in any tubular abnormalities in mice  [29] . Ap-
proximately 20% of calcium is reabsorbed in the thick 
ascending limb of Henle’s loop (TAL) through a para-
cellular pathway involving claudin 16 and 19  [30] . This 
pathway is also used for the reabsorption of magnesium 
and sodium. Thus, defects in it are associated with renal 
magnesium loss and hypomagnesaemia. As this path-
way is driven by and involved in sodium chloride reab-
sorption in TAL, polyuria and hypokalemic, hypochlo-
remic metabolic alkalosis are often associated  [31] . This 
would fit with the trend for electrolytes identified here, 
as well as with the reported association with a Bartter-
like phenotype  [14] . Approximately 15% of filtered cal-
cium is reabsorbed in the distal convoluted tubule and 
connecting tubule via a transcellular pathway involving 
TRPV5 and TRPV6  [32] . So far, no human disease has 
been associated with dysfunction of these channels, so 
the phenotype in humans is unclear. Given the expres-
sion of INSR along the entire nephron, it could, of 
course, also be a combination of altered calcium han-
dling in all these segments.
 A recent report details an association of RMS with 
medullary sponge kidney  [13] . We are unable to confirm 
or refute this association in our series, as medullary 
sponge kidney is a diagnosis made by the typical appear-
ance of the kidneys on an intravenous pyelogram and 
none of our patients had this examination performed.
 Conclusion 
 Mutations in  INSR in man lead to abnormalities in 
kidney function, most prominently to hypercalciuria and 
nephrocalcinosis, suggesting an important role for INSR 
in renal calcium handling. In addition, there was a trend 
towards hypokalemic, hypochloremic alkalosis and hy-
pomagnesemia. Further investigations are needed to dis-
sect the underlying mechanisms. 
 Our findings are in contrast to reports from mice, 
where specific deletion of the insulin receptor is associ-
ated with marked albuminuria and histological features 
reminiscent of diabetic nephropathy  [9] , as well as en-
hanced sodium reabsorption  [8] . These discrepant results 
suggest that there may be differences between men and 
mice when it comes to the function of the insulin receptor 
in the kidney.
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